Lamb Weston (NYSE:LW – Get Free Report) had its target price upped by equities researchers at TD Cowen from $61.00 to $65.00 in a report released on Tuesday, Benzinga reports. The firm currently has a “hold” rating on the specialty retailer’s stock. TD Cowen’s price objective would indicate a potential downside of 0.96% from the company’s previous close.
A number of other brokerages also recently weighed in on LW. Wells Fargo & Company lowered their price objective on shares of Lamb Weston from $98.00 to $70.00 and set an “overweight” rating for the company in a research report on Friday, July 26th. Bank of America raised their price target on Lamb Weston from $66.00 to $68.00 and gave the stock a “neutral” rating in a report on Tuesday, September 17th. Consumer Edge cut Lamb Weston from an “overweight” rating to an “equal weight” rating in a research note on Friday, July 26th. JPMorgan Chase & Co. reduced their price objective on shares of Lamb Weston from $108.00 to $63.00 and set an “overweight” rating for the company in a report on Thursday, July 25th. Finally, Citigroup lifted their price target on shares of Lamb Weston from $72.00 to $75.00 and gave the stock a “buy” rating in a research report on Monday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Lamb Weston presently has a consensus rating of “Moderate Buy” and a consensus price target of $80.70.
Read Our Latest Analysis on LW
Lamb Weston Stock Up 1.1 %
Lamb Weston (NYSE:LW – Get Free Report) last issued its earnings results on Wednesday, July 24th. The specialty retailer reported $0.78 EPS for the quarter, missing the consensus estimate of $1.24 by ($0.46). The firm had revenue of $1.61 billion during the quarter, compared to analyst estimates of $1.71 billion. Lamb Weston had a return on equity of 44.06% and a net margin of 11.22%. Sell-side analysts predict that Lamb Weston will post 4.54 EPS for the current fiscal year.
Insider Activity at Lamb Weston
In related news, Director William G. Jurgensen purchased 10,000 shares of Lamb Weston stock in a transaction on Friday, July 26th. The stock was purchased at an average cost of $55.43 per share, with a total value of $554,300.00. Following the acquisition, the director now directly owns 173,377 shares in the company, valued at $9,610,287.11. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 1.66% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in LW. Sanctuary Advisors LLC acquired a new position in shares of Lamb Weston in the 2nd quarter worth approximately $1,106,000. Maven Securities LTD bought a new position in shares of Lamb Weston during the second quarter valued at $504,000. Cetera Investment Advisers boosted its stake in shares of Lamb Weston by 57.5% in the 2nd quarter. Cetera Investment Advisers now owns 30,499 shares of the specialty retailer’s stock valued at $2,564,000 after purchasing an additional 11,138 shares in the last quarter. EP Wealth Advisors LLC lifted its holdings in Lamb Weston by 6.3% during the 2nd quarter. EP Wealth Advisors LLC now owns 4,037 shares of the specialty retailer’s stock valued at $339,000 after purchasing an additional 239 shares during the last quarter. Finally, Kimelman & Baird LLC acquired a new position in shares of Lamb Weston in the 2nd quarter worth approximately $206,000. Institutional investors and hedge funds own 89.56% of the company’s stock.
Lamb Weston Company Profile
Lamb Weston Holdings, Inc produces, distributes, and markets frozen potato products worldwide. The company operates through four segments: Global, Foodservice, Retail, and Other. It offers frozen potatoes, commercial ingredients, and appetizers under the Lamb Weston brand, as well as under various customer labels.
Further Reading
- Five stocks we like better than Lamb Weston
- P/E Ratio Calculation: How to Assess Stocks
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Dividend Capture Strategy: What You Need to Know
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Lamb Weston Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lamb Weston and related companies with MarketBeat.com's FREE daily email newsletter.